Effect of Neoadjuvant Nab-Paclitaxel plus Gemcitabine Therapy on Overall Survival in Patients with Borderline Resectable Pancreatic Cancer: A Prospective Multicenter Phase II Trial (NAC-GA Trial)

导出原文传递

翻译打印收藏纠错

作者： Okada, Ken-ichi ^[1] ; Shimokawa, Toshio ^[2] ; Hirono, Seiko ^[3] ; Kawai, Manabu ^[4] ; Sho, Masayuki ^[5] ; Satoi, Sohei ^[6] ; Matsumoto, Ippei ^[7] ; Eguchi, Hidetoshi ^[8] ; Murakami, Yoshiaki ; Yamada, Suguru ; Doi, Mariko ; Yamaue, Hiroki

作者单位： Kindai Univ Hosp, Dept Surg, Sayama, Osaka, Japan ^[1] Wakayama Med Univ, Clin Study Support Ctr, Wakayama, Japan ^[2] Kansai Med Univ, Dept Surg, Hirakata, Osaka, Japan ^[3] Hiroshima Univ, Div Clin Med Sci, Dept Surg, Grad Sch Biomed Sci, Hiroshima, Japan ^[4] Wakayama Med Univ, Dept Surg 2, 811-1 Kimiidera, Wakayama 6418510, Japan ^[5] Nara Med Univ, Dept Surg, Kashihara, Nara, Japan ^[6] Nagoya Univ, Grad Sch Med, Dept Gastroenterol Surg Surg 2, Nagoya, Aichi, Japan ^[7] Osaka Univ, Dept Surg, Grad Sch Med, Suita, Osaka, Japan ^[8]

关键词 Nab-paclitaxel Gemcitabine Borderline resectable pancreatic cancer

发布时间 2018-03-24

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交